Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celcuity Inc. on August 26, 2026. The report discloses a significant corporate development regarding the Company's lead drug candidate, REVTORPYK (gedatolisib).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statement data.
Material Changes and Events
- Regulatory Submission: On August 26, 2026, Celcuity submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA).
- Indication: The sNDA is for REVTORPYK (gedatolisib) for the treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (ABC) with a PIK3CA mutation.
- Patient Population: The application targets patients who have progressed on or after treatment with at least one line of endocrine therapy.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the inherent uncertainty of FDA review. The submission of the sNDA represents a critical step toward potential market approval, but the filing does not state the expected timeline for FDA action or approval probability.
Investor Verification Checklist
- Verify the specific clinical data supporting the sNDA submission by reviewing the referenced press release (Exhibit 99.1).
- Monitor FDA communications for the acceptance of the sNDA and the establishment of a Prescription Drug User Fee Act (PDUFA) target action date.
- Assess the competitive landscape for PIK3CA-mutated breast cancer treatments to evaluate the potential market impact of REVTORPYK.
- Review the Company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not provide liquidity details.